Regulatory Authorities Worldwide are Scrutinizing GDPs During Inspections
This article was originally published in The Gold Sheet
Regulators worldwide are increasingly scrutinizing pharmaceutical manufacturers’ good distribution practices (GDPs) during GMP inspections as GDP regulations continue to proliferate, says an industry representative who discusses how to comply with different regulations and notes some of the challenges in instituting robust GDPs. USP is the latest player in the increasingly crowded GDP arena.
You may also be interested in...
The European Commission needs to fine tune its good distribution practices (GDP) guideline, the pharmaceutical industry said in comments on a proposed draft revision. Key issues include segregating EU and non-EU product, transportation vs. storage conditions, applicability to investigational products and time limits for transportation hubs.
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.